Plain-English translation of NCT07072208 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a combination of four drugs—pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin—can help elderly patients with a type of aggressive lymphoma called diffuse large B-cell lymphoma (DLBCL). The study starts with three of the medications for three weeks to see how well your cancer responds, and if it responds well enough, you'll then receive all four medications together for six additional cycles.
Elderly patients with this type of lymphoma often struggle to tolerate standard treatments because of their age and health conditions. This trial is exploring whether this specific four-drug combination might be easier to tolerate while still effectively fighting the cancer.
You likely qualify if…
You likely don't qualify if…
You'll receive three medications by injection or infusion during a 3-week initial phase, followed by imaging scans to see how well your cancer is responding. If the cancer shrinks by at least 25%, you'll continue to the main treatment phase, where you'll receive all four medications in 3-week cycles for 6 cycles (about 4–5 months total). You'll have regular blood tests and imaging scans throughout to monitor how you're doing and watch for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China